alphaveJUBLPHARMA₹1,026.00

Jubilant Pharmova Ltd.

Annual Quarterly₹ CrorePeersGLAND PPLPHARMA KIMS INDGN ONESOURCE GRANULES PFIZER POLYMEDMcap ₹16,211 Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,680.3	1,677.1	1,758.6	1,731.7	1,752.3	1,821.7	1,928.8	1,900.7	1,966.4	2,122.5	2,290.0	2,229.4
Other Income	9.9	35.8	14.4	14.0	21.7	9.2	11.9	12.0	9.8	20.5	23.7	19.9
Total Income	1,690.2	1,712.9	1,773.0	1,745.7	1,774.0	1,830.9	1,940.7	1,912.7	1,976.2	2,143.0	2,313.7	2,249.3
Expenses
+ Cost of Materials Consumed	464.4	431.5	497.3	465.3	469.0	467.0	584.0	520.5	564.9	592.1	642.8	638.3
+ Purchases of Stock-in-Trade	58.4	71.8	53.9	61.8	69.3	81.2	84.8	73.0	73.6	82.0	84.5	86.9
+ Changes in Inventories	34.5	32.6	-23.8	34.6	16.5	26.2	-42.7	24.7	-42.0	42.2	-14.0	23.5
+ Employee Benefit Expense	531.8	581.5	555.0	552.9	564.3	560.1	590.6	591.1	636.2	706.4	766.9	753.5
+ Finance Costs	66.1	71.3	73.0	71.0	61.0	55.6	52.7	49.0	50.2	56.1	56.5	54.2
+ Depreciation & Amortisation	96.6	94.6	101.0	90.7	91.4	91.3	95.2	98.1	104.8	120.7	116.8	127.3
+ Other Expenses	349.4	341.7	404.8	365.6	343.8	399.8	366.7	401.8	392.3	410.3	470.5	479.2
Total Expenses	1,601.2	1,625.0	1,661.2	1,641.9	1,615.3	1,681.2	1,731.3	1,758.2	1,780.0	2,009.8	2,124.0	2,162.9
EBITDA	241.8	218.0	271.4	251.5	289.4	287.4	345.4	289.6	341.4	289.5	339.3	248.0
EBIT	145.2	123.4	170.4	160.8	198.0	196.1	250.2	191.5	236.6	168.8	222.5	120.7
Profit
PBT before Exceptional Items	89.0	87.9	111.8	103.8	158.7	149.7	209.4	154.5	196.2	133.2	189.7	86.4
+ Exceptional Items	0.0	0.0	-168.9	395.9	-14.2	-18.9	-3.3	0.0	-5.8	-39.7	-13.7	0.0
Pretax Income	89.0	87.9	-57.1	499.7	144.5	130.8	206.1	154.5	190.4	93.5	176.0	86.4
+ Current Tax	35.1	45.1	108.1	26.1	40.0	32.3	114.8	37.5	36.1	21.6	65.5	29.6
+ Deferred Tax	0.8	-10.5	-100.0	-8.2	1.9	-2.5	-60.1	14.4	34.3	16.0	-8.8	0.4
Tax Expense	35.9	34.6	8.1	17.9	41.9	29.8	54.7	51.9	70.4	37.6	56.7	30.0
+ Share of Associates & JVs	9.0	13.1	3.4	0.0	-0.1	-0.3	-0.1	-0.1	-0.1	-0.1	0.0	0.0
Net Income	62.1	66.4	-61.8	481.8	102.5	100.7	151.3	102.5	119.9	55.8	119.3	56.4
+ Net Income — Continuing Ops	53.1	53.3	-65.2	481.8	102.6	101.0	151.4	102.6	120.0	55.9	119.3	56.4
+ Other Comprehensive Income	34.2	17.0	-6.6	-3.9	30.0	63.5	-4.6	41.1	160.4	62.4	281.9	-19.1
Total Comprehensive Income	96.3	83.4	-68.4	477.9	132.5	164.2	146.7	143.6	280.3	118.2	401.2	37.3
Net Income to Common	62.5	66.8	-58.6	482.1	102.8	100.9	153.6	102.9	120.3	55.9	119.4	56.5
Minority Interest	-0.4	-0.4	-3.2	-0.3	-0.3	-0.2	-2.3	-0.4	-0.4	-0.1	-0.1	-0.1
Per Share
Basic EPS	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57
Diluted EPS	3.94	4.20	-3.68	30.35	6.46	6.36	9.68	6.47	7.57	3.52	7.52	3.56
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-4.6	41.1	160.4	62.4	281.9	-19.1
+ Items NOT to be Reclassified to P&L	-0.7	-0.7	2.2	-0.4	-0.4	-0.3	0.8	-0.4	-1.3	0.4	7.7	0.1
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.4	-0.1	-0.5	0.1	0.4	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.2	-0.3	1.8	-0.1	-0.2	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	34.7	17.4	-7.0	-3.6	30.2	—	-5.8	41.4	161.2	62.1	—	-19.2
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	0.0	-274.6	0.0
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	0.0	0.0	0.0	-63.7	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	34.3	83.8	-65.1	478.2	132.8	164.8	148.9	144.1	281.3	118.1	401.4	37.4
Comprehensive Income — Non-controlling Interests	-0.1	-0.4	-3.3	-0.3	-0.3	-0.6	-2.2	-0.5	-1.0	0.1	-0.2	-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57
Diluted EPS — Continuing Operations	3.94	4.20	-3.68	30.35	6.46	6.36	9.68	6.47	7.57	3.52	7.52	3.56
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,123.0	1,141.2	1,231.2	1,170.0	1,197.5	1,247.3	1,302.7	1,282.5	1,369.9	1,406.2	1,576.7	1,480.7
Gross Margin %	66.83	68.05	70.01	67.56	68.34	68.47	67.54	67.48	69.67	66.25	68.85	66.42
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	89.0	87.9	111.8	103.8	158.7	149.7	209.4	154.5	196.2	133.2	189.7	86.4
− Exceptional Items (reconciliation)	0.0	0.0	-168.9	395.9	-14.2	-18.9	-3.3	0.0	-5.8	-39.7	-13.7	0.0
Net Income Adj (tax-effected)	62.1	66.4	107.1	100.1	112.6	115.3	153.7	102.5	123.6	79.5	128.6	56.4
EPS Adj	3.94	4.22	6.39	6.32	7.11	7.29	9.87	6.49	7.82	5.02	8.14	3.57
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8	15.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.